This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Todd, D. Articles by Costenbader, K. Search for Related Content PubMed PubMed Citation Articles by Todd, D. Articles by Costenbader, K. Social Bookmarking                         What's this?

Dyspnoea in a young woman with active systemic lupus erythematosus

Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Arthritis Center, Boston, Massachusetts, USAdtodd1{at}partners.org

KH Costenbader

Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Arthritis Center, Boston, Massachusetts, USA

Diffuse alveolar haemorrhage (DAH) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). We present the case of a 24-year-old Cambodian woman with SLE followed in the Brigham and Women’s Hospital Lupus Center in Boston, Massachusetts. She presented with dyspnoea and chest pain and was found to have DAH that required a prolonged hospitalization that was complicated by recurrent DAH episodes and multiple infections. We discuss the diagnostic approach and management of patients with SLE-associated DAH as well as treatment options for refractory disease. Emerging therapies include plasmapheresis, the anti-CD20 monoclonal antibody rituximab and recombinant activated Factor VII therapy. In addition, we review the literature to date and compile what is known about the epidemiology, presenting features, diagnostic findings, management and outcomes in this condition. We found that DAH has been reported in 1.9% of patients with SLE. These patients were mostly female (88%) and young (mean age 30.2 years). Common presenting features included dyspnoea (94%), anaemia (97%) and new radiographic chest infiltrate (99%). Bronchoscopy, when performed, identified DAH in 90% of cases. Corticosteroids were the mainstay of care, and usage of cyclophosphamide varied by report. Despite recent advances in therapy, mortality has not improved substantially (48% overall survival versus 53% survival in reports published since 1993).

Key Words: diffuse alveolar hemorrhage • epidemiology • plasmapheresis • review • rituxima • systemic lupus erythematosus

Lupus, Vol. 18, No. 9, 777-784 (2009)
DOI: 10.1177/0961203309104860


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?